{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:25:13Z","timestamp":1767893113759,"version":"3.49.0"},"reference-count":24,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1536\/ihj.16-285","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T22:07:24Z","timestamp":1494540444000},"page":"416-421","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension"],"prefix":"10.1536","volume":"58","author":[{"given":"Yuhei","family":"Shiga","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Inoue Hospital"},{"name":"Fujisawa Clinic"},{"name":"Shirotani Hospital"},{"name":"Division of Cardiology, Izumi General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Department of Molecular Cardiovascular Therapeutics, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Motozato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Division of Cardiology, Izumi General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Norimatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Fujisawa Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Hitaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Inoue Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuwano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Inoue","sequence":"additional","affiliation":[{"name":"Inoue Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asao","family":"Inoue","sequence":"additional","affiliation":[{"name":"Inoue Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Fujisawa","sequence":"additional","affiliation":[{"name":"Fujisawa Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Shirotani","sequence":"additional","affiliation":[{"name":"Shirotani Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Izumi General Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehito","family":"Ideishi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keijiro","family":"Saku","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Inoue Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Imaizumi S, Miura S, Yahiro E, Uehara Y, Komuro I, Saku K. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers. Curr Pharm Des 2013; 19: 3002-8. (Review)","DOI":"10.2174\/1381612811319170005"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Adachi Y, Sakakura K, Wada H, <i>et al<\/i>. Determinants of left ventricular systolic function improvement following coronary artery revascularization in heart failure patients with reduced ejection fraction (HFrEF). Int Heart J 2016; 57: 565-72.","DOI":"10.1536\/ihj.16-087"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Miura S, Karnik SS and Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12: 1-7. (Review)","DOI":"10.1177\/1470320310370852"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fujino M, Miura S, Kiya Y, <i>et al<\/i>. A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects. Hypertens Res 2010; 33: 1044-52.","DOI":"10.1038\/hr.2010.135"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ikeda Y, Kumagai H, Motozawa Y, Suzuki J, Komuro I. Next generation ARBs. Going beyond modulation of the renin-angiotensin system. Int Heart J 2015; 56: 585-6.","DOI":"10.1536\/ihj.15-295"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res 2012; 35: 552-8.","DOI":"10.1038\/hr.2012.8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. White WB, Weber MA, Sica D, <i>et al<\/i>. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.","DOI":"10.1161\/HYPERTENSIONAHA.110.163402"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bakris GL, Sica D, Weber M, <i>et al<\/i>. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens 2011; 13: 81-8.","DOI":"10.1111\/j.1751-7176.2010.00425.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sica D, White WB, Weber MA, <i>et al<\/i>. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens 2011; 13: 467-72.","DOI":"10.1111\/j.1751-7176.2011.00482.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ojima M, Igata H, Tanaka M, <i>et al<\/i>. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801-8.","DOI":"10.1124\/jpet.110.176636"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ogihara T, Kikuchi K, Matsuoka H, <i>et al<\/i>; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.","DOI":"10.1038\/hr.2009.34"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. White WB, Cuadra RH, Lloyd E, Bakris GL, Kupfer S. Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. J Hypertens 2016; 34: 788-97.","DOI":"10.1097\/HJH.0000000000000839"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sezai A, Osaka S, Yaoita H, <i>et al<\/i>. Changeover trial of azilsartan and olmesartan comparing effects on the renin-angiotensin-aldosterone system in patients with essential hypertension after cardiac surgery (CHAOS Study). Ann Thorac Cardiovasc Surg 2016; 22: 161-7.","DOI":"10.5761\/atcs.oa.16-00054"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.","DOI":"10.1001\/jama.288.23.2981"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.","DOI":"10.1016\/S0140-6736(01)06411-X"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yamagata K, Ishida K, Sairenchi T, <i>et al<\/i>. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71: 159-66.","DOI":"10.1038\/sj.ki.5002017"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013; 36: 134-9.","DOI":"10.1038\/hr.2012.147"},{"key":"19","unstructured":"19. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy 2004; 24: 697-702."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2007; 23: 1166-79.","DOI":"10.1016\/S0149-2918(01)80099-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 2007; 320: 211-7.","DOI":"10.1124\/jpet.106.112755"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ohta Y, Tsuchihashi T and Kiyohara K. Usefulness of conventional methods of the classification of hyperuricemia in hypertensive patients with hyperuricemia. Gout and Nucleic Acid Metabolism 2012; 36: 9-13.","DOI":"10.6032\/gnam.36.9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Shiga Y, Miura S, Mitsutake R, <i>et al<\/i>. Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan\/hydrochlorothiazide in patients with uncontrolled hypertension. J Renin Angiotensin Aldosterone Syst 2012; 13: 394-400.","DOI":"10.1177\/1470320312439493"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shiga Y, Miura S, Norimatsu K, <i>et al<\/i>. Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2015; 16: 1078-84.","DOI":"10.1177\/1470320314529358"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-285\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T14:06:53Z","timestamp":1569334013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/58\/3\/58_16-285\/_article"}},"subtitle":["A Randomized and Prospective Study (CANZONE Study)"],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.16-285","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}